Doxorubicin-loaded delta inulin conjugates for controlled and targeted drug delivery: Development, characterization, and in vitro evaluation
Artikel i vetenskaplig tidskrift, 2019

Delta inulin, also known as microparticulate inulin (MPI), was modified by covalently attaching doxorubicin to its nanostructured surface for use as a targeted drug delivery vehicle. MPI is readily endocytosed by monocytes, macrophages, and dendritic cells and in this study, we sought to utilize this property to develop a system to target anti-cancer drugs to lymphoid organs. We investigated, therefore, whether MPI could be used as a vehicle to deliver doxorubicin selectively, thereby reducing the toxicity of this antibiotic anthracycline drug. Doxorubicin was covalently attached to the surface of MPI using an acid-labile linkage to enable pH-controlled release. The MPI-doxorubicin conjugate was characterized using FTIR and SEM, confirming covalent attachment and indicating doxorubicin coupling had no obvious impact on the physical nanostructure, integrity, and cellular uptake of the MPI particles. To simulate the stability of the MPI-doxorubicin in vivo, it was stored in artificial lysosomal fluid (ALF, pH 4.5). Although the MPI-doxorubicin particles were still visible after 165 days in ALF, 53% of glycosidic bonds in the inulin particles were hydrolyzed within 12 days in ALF, reflected by the release of free glucose into solution. By contrast, the fructosidic bonds were much more stable. Drug release studies of the MPI-doxorubicin in vitro, demonstrated a successful pH-dependent controlled release effect. Confocal laser scanning microscopy studies and flow cytometric analysis confirmed that when incubated with live cells, MPI-doxorubicin was effciently internalized by immune cells. An assay of cell metabolic activity demonstrated that the MPI carrier alone had no toxic effects on RAW 264.7 murine monocyte/macrophage-like cells, but exhibited anti-cancer effects against HCT116 human colon cancer cells. MPI-doxorubicin had a greater anti-cancer cell effect than free doxorubicin, particularly when at lower concentrations, suggesting a drug-sparing effect. This study establishes that MPI can be successfully modified with doxorubicin for chemotherapeutic drug delivery.

Targeted delivery

Anticancer therapy

Inulin

Doxorubicin

pH sensitive

Intracellular drug release

Advax

Författare

[Person 30ddf963-57a6-42ec-b81b-91bed8a421d8 not found]

[Person 86ed0fe4-58b0-42fd-b341-9712b7cdf827 not found]

[Person a233dbe8-1042-4968-afb1-5e8c6eebe2b2 not found]

[Person 3f24d634-a09e-4d69-8f88-596bb1bf780d not found]

[Person 334cb4b5-290a-41a0-831d-62db2fbd1242 not found]

[Person 49162bb1-3d74-4ba6-afcf-36b616f066ab not found]

[Person 74f6e11d-d9b7-4c88-87a9-3e53bd60f137 not found]

[Person f198106a-d78c-498e-9822-2e7afb927bb0 not found]

[Person 55b149be-061c-4a95-bb9d-4859603094af not found]

[Person 755a7a12-0cc4-4fa4-a86e-c8238d5cc7db not found]

[Person 9d02a9d4-8e6b-432c-9efc-c080105e807b not found]

Pharmaceutics

1999-4923 (ISSN)

Vol. 11 11 581

Ämneskategorier

Cellbiologi

Cell- och molekylärbiologi

Farmakologi och toxikologi

DOI

10.3390/pharmaceutics11110581

Mer information

Senast uppdaterat

2019-11-19